JLABS in the media

Nov 2 2016FortuneKia Kokalitcheva

How Drug Development Cycles May Be 'Getting Smaller and Smaller'

The rise of new technologies, such as 3D printing and CRISPR, a new gene-editing technology, is also contributing to the shortening of drug development cycles, said Dr. Lesley Stolz of Johnson & Johnson Innovation, JLABS.

Link to article: 
http://fortune.com/2016/11/02/drug-development-testing-success-approval/

Share